Poor
Mostly Aligned
Patient Risk:
Low
Summary
Most clinical/indication-related statements are broadly consistent with the provided label indications, but many pricing/insurance/generics/timelines claims are not supported by the provided FDA prescribing information excerpts and cannot be validated against them. Several statements contain information unrelated to labeling content provided.
Category Scores
Accurate Statements
Sprycel is a brand-name version of dasatinib.
The provided label excerpt identifies SPRYCEL (dasatinib) as the product name tied to the active ingredient dasatinib (Drug: SPRYCEL; Active ingredient(s): dasatinib).
Sprycel is used for certain blood cancers such as chronic myeloid leukemia.
Indications include treatment of Ph+ CML (chronic phase) and additional Ph+ CML phases/resistance/intolerance (Section 1 INDICATIONS AND USAGE).
Sprycel is used for certain blood cancers such as Philadelphia chromosome–positive leukemias.
Indications include Philadelphia chromosome-positive (Ph+) leukemias including Ph+ CML and Ph+ ALL (Section 1 INDICATIONS AND USAGE).
Unsupported Statements
Sprycel price varies depending on factors like dose strength.
No pricing information is present in the provided FDA label excerpts.
Sprycel price varies depending on whether a person pays cash versus using insurance.
No pricing/insurance/cost-share information is present in the provided FDA label excerpts.
Sprycel price varies depending on location and pharmacy pricing or discounts.
No pricing/location/discount information is present in the provided FDA label excerpts.
Specific current Sprycel pricing depends on the exact strength and pack size.
No current pricing, pack size, or strength-dependent pricing statements are present in the provided FDA label excerpts.
Specific current Sprycel pricing can change over time.
No pricing/time-variation statements are present in the provided FDA label excerpts.
Switching from brand Sprycel to a lower-cost equivalent may reduce out-of-pocket cost if one is available and appropriate.
No generics/substitution/out-of-pocket cost guidance is present in the provided FDA label excerpts.
Using manufacturer or pharmacy assistance programs may reduce out-of-pocket cost, with availability depending on eligibility and timing.
No patient assistance program or out-of-pocket cost statements are present in the provided FDA label excerpts.
Checking whether a different formulation or dose strength changes total monthly cost could reduce out-of-pocket cost.
No cost/financial counseling statements are present in the provided FDA label excerpts.
Once generic dasatinib enters, brand pricing often drops.
No statements about generic entry affecting brand pricing are present in the provided FDA label excerpts.
The presence of generics can change out-of-pocket costs, especially with insurance formularies.
No statements about formularies, out-of-pocket costs, or generic impact on patient payment are present in the provided FDA label excerpts.
Patent or litigation timelines related to generics can influence how quickly discounts appear.
No statements about patents/litigation affecting discounts are present in the provided FDA label excerpts.
Contradictions
Important Omissions
For the clinical/indication-related claims, the label contains more specific eligibility details (e.g., adult vs pediatric, Ph+ status, chronic vs accelerated/blast phase, resistance/intolerance to prior therapy, and combination with chemotherapy for pediatric Ph+ ALL). The AI claims were generalized and omitted these label qualifiers.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported statements are predominantly about pricing/cost and do not directly instruct dosing or safety use. Generalized indication wording could be less precise than labeling qualifiers but does not by itself constitute a dosing/safety contradiction based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims concern drug pricing, insurance coverage, generic timing, and assistance programs, none of which are supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to labeling-supported content (e.g., indications and dosing/administration elements). Remove or rephrase all pricing/cost/insurance/generics/timeline assertions unless supported by an FDA-approved source provided in the prompt.